The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare outcomes in patients undergoing lung transplantation, using 2 different induction therapies. Primary outcome is survival and secondary outcomes include freedom from infection and freedom from rejection.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Daclizumab

Criteria

Inclusion Criteria:

• All patients accepted and listed for lung transplantation will be considered for randomization

Exclusion Criteria:

• Patients who demonstrate hemodynamic instability, requiring inotropes for greater than 48 hours prior to transplant

• Severe reperfusion pulmonary edema or primary graft dysfunction requiring FiO2 of > 50% and PEEP > 10 cm for greater than 48 hours prior to transplant

• Preoperative renal insufficiency (CrCl < 50 gm.d or serum creatinine > 2.0)

• Pre-operative panel reactive antibodies PRA

• Preoperative recipient bacterial or fungal colonization

• Preoperative antimicrobial suppressive therapy